Skip to main content
. 2023 Nov 16;18(4):956–968. doi: 10.1002/1878-0261.13293

Fig. 1.

Fig. 1

Pathogenic alterations in tissue NGS analysis (N = 74), blood‐derived cfDNA analysis (N = 72) and immune profiling markers with RNA sequencing (N = 12) among patients with CUP. (A) Pathogenic alterations in tissue NGS analysis among patients with CUP patients (N = 74). Numbers shown are percent of patients with the specified alteration. Included the genes with frequency of > 5%. See Table S1 for complete list of genomic alterations found by tissue NGS; percentage represents per cent of patient with alteration. (B) Pathogenic alterations in blood‐derived cfDNA analysis among patients with CUP (N = 72). Numbers shown are per cent of patients with the specified alteration. Included the genes with frequency of > 4%. See Table S2 for complete list of genomic alterations found by cfDNA assay; Percentage represents per cent of patient with alteration. (C) Immune profiling markers with RNA sequencing (OmniSeq) among patients with CUP (N = 12). Percentage represents per cent of patient with indicated expression. See also Table S3.